408 related articles for article (PubMed ID: 20642374)
1. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
3. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW; Wyllie MG
BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
6. A new testosterone gel (fortesta) for hypogonadism.
Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
[TBL] [Abstract][Full Text] [Related]
7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
8. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
[TBL] [Abstract][Full Text] [Related]
9. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
10. Recent trends in the treatment of testosterone deficiency syndrome.
Hong BS; Ahn TY
Int J Urol; 2007 Nov; 14(11):981-5. PubMed ID: 17956520
[TBL] [Abstract][Full Text] [Related]
11. Testosterone metabolism and replacement therapy in patients with end-stage renal disease.
Johansen KL
Semin Dial; 2004; 17(3):202-8. PubMed ID: 15144546
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
13. Testosterone treatment comes of age: new options for hypogonadal men.
Nieschlag E
Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
15. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
16. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
18. Hypogonadal men treated with oral testosterone undecanoate.
Sarris S; Swyer GI; Lawrence DM
Acta Eur Fertil; 1977 Dec; 8(4):297-9. PubMed ID: 610314
[TBL] [Abstract][Full Text] [Related]
19. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
[TBL] [Abstract][Full Text] [Related]
20. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]